Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
Healthcare
$76.99 +1.71%
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
52W Low $9.10High $35.80
Volume 0.00M
Average 0.30M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$70.66M
FY 2025 · Annual
Net Income
-$69.38M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 36K | 0 | 9K | 39K | 64K |
| Gross Profit | (36K) | 0 | (9K) | (39K) | (64K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.85M | 5.59M | 21.86M | 21.19M | 58.25M |
| Selling, General & Admin | 7.63M | 8.3M | 10.62M | 15.37M | 12.41M |
| Operating Expenses | 21.49M | 13.9M | 32.48M | 36.56M | 70.66M |
| Depreciation & Amortization | 36K | 36K | 9K | 39K | 64K |
| EBITDA | (21.67M) | (13.84M) | (31.47M) | (35.44M) | (68.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.49M) | (13.9M) | (32.49M) | (36.6M) | (70.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.12M | 1.31M | 2.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (222K) | 17K | 1.01M | 1.12M | 2.32M |
| Income Before Tax | (21.71M) | (13.88M) | (31.48M) | (35.48M) | (68.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.04M |
| Net Income | (21.71M) | (13.86M) | (31.48M) | (35.48M) | (69.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| EPS (Diluted) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| 558.71K | 695.34K | 1.26M | 2.92M | 147.18M | |
| 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
FBRX Earnings Waterfall · TTM
NASDAQ:FBRX · Revenue to Net Income
Key Ratios
EPS$-4.58
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-25.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$75.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.58, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 14D9/A | SC 14D9/A filing | Aug 21, 2026 | |
| SC TO-T/A | SC TO-T/A filing | Aug 19, 2026 | |
| SC 14D9/A | SC 14D9/A filing | Aug 19, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 13, 2026 |
How much revenue does FBRX generate?
Forte Biosciences, Inc. (FBRX) reported $0.00 of revenue in fiscal 2025.
Is FBRX profitable?
Forte Biosciences, Inc. (FBRX) reported -$69.38M of net income.
Continue the stock analysis
Jump to another research area for this company.